News stories about Heat Biologics (NASDAQ:HTBX) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Heat Biologics earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 48.353983933927 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
HTBX stock traded down $0.14 during mid-day trading on Thursday, hitting $2.11. 18,978 shares of the company were exchanged, compared to its average volume of 1,347,099. Heat Biologics has a 1-year low of $1.09 and a 1-year high of $7.90.
Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.05). The company had revenue of $0.75 million for the quarter. Heat Biologics had a negative return on equity of 182.19% and a negative net margin of 543.30%.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.